Abstract
Rosai–Dorfman–Destombes disease (RDD) is a rare histiocytosis characterized by accumulation of S100 + , CD68 + , and CD1a- histiocytes, with emperipolesis. It occurs predominantly in black adolescents and young adults, but rarely in Japanese children. Recently, oncogenic mutations in mitogen-activated protein kinase (MAPK) pathway genes were reported in 30–50% of patients with RDD, and several studies have described treatment of adult patients with MAPK inhibitors. Here, we present the case of a Japanese boy with refractory RDD without signs of cardiofaciocutaneous (CFC) syndrome who harbored MAP2K1 p.Lys59del and responded to trametinib. The patient had lymph node, nasal cavity, kidney, upper respiratory tract, and intracranial involvement. RDD progressed after multi-agent chemotherapy, but responded to trametinib (0.025 mg/kg). Trametinib did not eliminate the mass lesions, but trametinib plus minimal prednisolone (0.1 mg/kg) resulted in a good outcome for more than 15 months, without significant adverse effects. MAP2K1 p.Lys59del has been described as a germline mutation in a patient with CFC syndrome, but not as a somatic mutation in patients with malignancies. Trametinib may be a promising drug for children with RDD that is refractory to multi-agent chemotherapy. Its long-term efficacy and safety alone and in combination with chemotherapy should be investigated.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12185-024-03818-9/MediaObjects/12185_2024_3818_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12185-024-03818-9/MediaObjects/12185_2024_3818_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs12185-024-03818-9/MediaObjects/12185_2024_3818_Fig3_HTML.jpg)
References
Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877–90.
Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73:697–705.
Chen HH, Zhou SH, Wang SQ, Teng XD, Fan J. Factors associated with recurrence and therapeutic strategies for sinonasal Rosai-Dorfman disease. Head Neck. 2012;34:1504–13.
Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, et al. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017;30:1367–77.
Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019;25:1839–42.
Hélias-Rodzewicz Z, Donadieu J, Terrones N, Barkaoui MA, Lambilliotte A, Moshous D, et al. Molecular and clinicopathologic characterization of pediatric histiocytoses. Am J Hematol. 2023;98:1058–69.
Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, et al. Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status. JAMA Oncol. 2022;8:1816–20.
Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan G, et al. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis. Blood Adv. 2023;7:3984–92.
Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Nishimura R, Wakita H, et al. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 2013;97:103–8.
Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016;104:99–109.
Acosta-Medina AA, Abeykoon JP, Go RS, Goyal G, Ravindran A, Schram SM, et al. BRAF testing modalities in histiocytic disorders: comparative analysis and proposed testing algorithm. Am J Clin Pathol. 2023;160:483–9.
Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, Jones KL, et al. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A. 2007;143A:1472–80.
Kinoshita-Kikuta E, Kinoshita E, Ueda S, Ino Y, Kimura Y, Hirano H, et al. Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers. Biochim Biophys Acta Proteins Proteom. 2019;1867:62–70.
National Center for Biotechnology Information. ClinVar; [VCV000222074.4], https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000222074.4 (Accessed Aug. 10, 2023)
Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, et al. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023;7:3806–15.
Gouda MA, Subbiah V. Expanding the benefit: Dabrafenib/Trametinib as tissue-agnostic therapy for BRAF V600E-positive adult and pediatric solid tumors. Am Soc Clin Oncol Educ Book. 2023;43: e404770.
Bouffet E, Geoerger B, Moertel C, Whitlock JA, Aerts I, Hargrave D, et al. Efficacy and safety of trametinib monotherapy or in combination with Dabrafenib in pediatric BRAF V600-mutant low-grade glioma. J Clin Oncol. 2023;41:664–74.
Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37:2857–65.
Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, et al. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH. Blood Adv. 2023;7:5246–57.
Funding
This study was supported by grants for Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED; JP23ck0106852).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
New findings: This report highlights the efficacy of trametinib in a pediatric patient with nodal and extra-nodal Rosai–Dorfman–Destombes disease who was refractory to multi-agent chemotherapy. The lesional cells harbored MAP2K1 p.Lys59del, which has so far only been reported as a germline mutation in a patient with cardiofaciocutaneous syndrome.
About this article
Cite this article
Taneyama, Y., Morimoto, A., Ochiai, H. et al. Trametinib for a child with refractory Rosai–Dorfman–Destombes disease harboring a novel somatic mutation in MAP2K1. Int J Hematol (2024). https://doi.org/10.1007/s12185-024-03818-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12185-024-03818-9